Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults

Philippe Lesprit; Gaëlle Pédrono; Jean Michel Molina; Cécile Goujard; Pierre Marie Girard; Nathalie Sarrazin; Christine Katlama; Patrick Yéni; Pascale Morineau; Jean François Delfraissy; Geneviève Chêne; Yves Lévy; P. Lesprit; Y. Levy; N. Sarrazin; G. Pedrono; C. Rabian; P. Bursachi; M. J. Commoy; J. F. Delfraissy; F. Denis; B. Fritzell; C. Goujard; R. Salamon; R. Tubiana; J. P. Viard; A. Krivitzky; M. Bentata; S. Makki; R. Mansouri; L. Guillevin; B. Jarousse; A. K. Klutse; G. Obenga; P. Honoré-Berlureau; Y. Baazia; S. Soreda; J. P. Clauvel; E. Oksenhendler; L. Gerard; J. Delgado; J. M. Molina; N. Colin De Verdière; P. Palmer; I. Madelaine; M. Dupon; J. M. Ragnaud; D. Neau; I. Raymond; I. Garrigue; J. P. Dupin; Ch Boitard; J. P. Viard; S. El Marsafy; R. Lahoulou; A. Mogenet; C. Broissand; J. F. Delfraissy; C. Goujard; D. Pereti; Y. Quertainmont; P. Robquin; O. Segeral; S. Poirier; M. T. Rannou; N. Idri; C. Le Tiec; D. Sicard; D. Salmon; O. Launay; B. Silbermann; C. Desaint; A. Krivine; C. Guérin; A. Sobel; Y. Lévy; P. Lesprit; A. S. Lascaux; Ch Chesnel; C. Jung; A. Miladi; C. Antoine; F. Bricaire; I. Boubezari; S. Pierre-François; L. Schneider; C. Seulié; M. H. Fievet; P. M. Girard; A. M. Béglé; F. Besse; R. Mouchotte; A. Charrois; A. Duaguenel-Nguyen; P. Yeni; I. Fournier; S. Lariven; B. Phung; P. Ralaïmazava; Ch Gaudebout; J. Gerbe; D. Descamps; S. LePoole; J. Reynes; P. André; V. Baillat; V. Le Moing; C. Merle; M. Vidal; J. M. Fondère; I. Roch-Torreilles; F. Raffi; P. Morineau; C. Allavena; B. Bonnet; H. Hue; E. Guarnier; A. Lepelletier; P. Perré; O. Aubry; S. Leautez; C. Leroy; I. Suaud; A. S. Poirier; A. Lepelletier; P. Dellamonica; V. Rahelinirina; M. A. Sereni; S. Benhamou; M. Ch Rigault; P. Massip; B. Marchou; M. Alvarez; E. Bonnet; L. Cuzin; M. Obadia; F. Balsarin; M. Barone; M. Heraud; I. Peyranne; F. Mentré; P. Morlat; N. Sarrazin; G. Pedrono; I. Tschöpe; G. Palmer

doi:10.1097/QAD.0b013e3282887e91

Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults

Philippe Lesprit, Gaëlle Pédrono, Jean Michel Molina, Cécile Goujard, Pierre Marie Girard, Nathalie Sarrazin, Christine Katlama, Patrick Yéni, Pascale Morineau, Jean François Delfraissy, Geneviève Chêne, Yves Lévy^*, P. Lesprit, Y. Levy^*, N. Sarrazin, G. Pedrono, C. Rabian, P. Bursachi, M. J. Commoy, J. F. DelfraissyF. Denis, B. Fritzell, C. Goujard, R. Salamon, R. Tubiana, J. P. Viard, A. Krivitzky, M. Bentata, S. Makki, R. Mansouri, L. Guillevin, B. Jarousse, A. K. Klutse, G. Obenga, P. Honoré-Berlureau, Y. Baazia, S. Soreda, J. P. Clauvel, E. Oksenhendler, L. Gerard, J. Delgado, J. M. Molina, N. Colin De Verdière, P. Palmer, I. Madelaine, M. Dupon, J. M. Ragnaud, D. Neau, I. Raymond, I. Garrigue, J. P. Dupin, Ch Boitard, J. P. Viard, S. El Marsafy, R. Lahoulou, A. Mogenet, C. Broissand, J. F. Delfraissy, C. Goujard, D. Pereti, Y. Quertainmont, P. Robquin, O. Segeral, S. Poirier, M. T. Rannou, N. Idri, C. Le Tiec, D. Sicard, D. Salmon, O. Launay, B. Silbermann, C. Desaint, A. Krivine, C. Guérin, A. Sobel, Y. Lévy^*, P. Lesprit, A. S. Lascaux, Ch Chesnel, C. Jung, A. Miladi, C. Antoine, F. Bricaire, I. Boubezari, S. Pierre-François, L. Schneider, C. Seulié, M. H. Fievet, P. M. Girard, A. M. Béglé, F. Besse, R. Mouchotte, A. Charrois, A. Duaguenel-Nguyen, P. Yeni, I. Fournier, S. Lariven, B. Phung, P. Ralaïmazava, Ch Gaudebout, J. Gerbe, D. Descamps, S. LePoole, J. Reynes, P. André, V. Baillat, V. Le Moing, C. Merle, M. Vidal, J. M. Fondère, I. Roch-Torreilles, F. Raffi, P. Morineau, C. Allavena, B. Bonnet, H. Hue, E. Guarnier, A. Lepelletier, P. Perré, O. Aubry, S. Leautez, C. Leroy, I. Suaud, A. S. Poirier, A. Lepelletier, P. Dellamonica, V. Rahelinirina, M. A. Sereni, S. Benhamou, M. Ch Rigault, P. Massip, B. Marchou, M. Alvarez, E. Bonnet, L. Cuzin, M. Obadia, F. Balsarin, M. Barone, M. Heraud, I. Peyranne, F. Mentré, P. Morlat, N. Sarrazin, G. Pedrono, I. Tschöpe, G. Palmer

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

119 Scopus citations

Abstract

OBJECTIVE: To evaluate whether a strategy combining a prime with a 7-valent conjugate pneumococcal vaccine (PCV) followed by a boost with the 23-valent polysaccharide vaccine (PPV) would improve immunogenicity against Streptococcus pneumoniae polysaccharides in HIV-infected patients. DESIGN: Randomized controlled phase II trial. METHODS: Two-hundred and twelve patients with CD4 cell counts of 200-500 cells/μl and HIV RNA< 4 log10 copies/ml, regardless of antiretroviral treatment, were randomized to receive either PCV at week 0 and PPV at week 4 (n = 106) or PPV alone at week 4 (n = 106). The proportion of responders to 0, 1-2, 3-4, 5-7 serotypes shared by the two vaccines was evaluated at week 8 and compared using a proportional odds model allowing for adjustment for CD4 cell count, HIV RNA and antiretroviral treatment. RESULTS: At week 8, the profile of response was better in the prime-boost group compared to the PPV group, as determined by the frequency of patients who reached both a twofold increase of serotype-specific IgG levels and IgG level ≥ 1 μg/ml [proportional odds ratio (OR), 2.09; 95% confidence interval (CI), 1.25-3.51; P = 0.005]. No differences in responders were found 4 weeks after PCV or PPV alone, suggesting that PCV primed for response to PPV. Early differences between groups remained significant at week 24 (proportional OR, 2.14; 95% CI, 1.30-3.54; P = 0.003). CONCLUSIONS: In a setting of practical care, a PCV prime-PPV boost strategy enhances the frequency, breadth and magnitude of antibody responses against SPP in HIV-infected adults.

Original language	English
Pages (from-to)	2425-2434
Number of pages	10
Journal	AIDS
Volume	21
Issue number	18
DOIs	https://doi.org/10.1097/QAD.0b013e3282887e91
State	Published - Dec 2007
Externally published	Yes

Keywords

Conjugate vaccine
HIV
Immunogenicity
Pneumococcal vaccine
Priming

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/QAD.0b013e3282887e91

Cite this

Lesprit, P., Pédrono, G., Molina, J. M., Goujard, C., Girard, P. M., Sarrazin, N., Katlama, C., Yéni, P., Morineau, P., Delfraissy, J. F., Chêne, G., Lévy, Y., Lesprit, P., Levy, Y., Sarrazin, N., Pedrono, G., Rabian, C., Bursachi, P., Commoy, M. J., ... Palmer, G. (2007). Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS, 21(18), 2425-2434. https://doi.org/10.1097/QAD.0b013e3282887e91

@article{429743fe1ff4467685ecf912c1cd8204,

title = "Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults",

abstract = "OBJECTIVE: To evaluate whether a strategy combining a prime with a 7-valent conjugate pneumococcal vaccine (PCV) followed by a boost with the 23-valent polysaccharide vaccine (PPV) would improve immunogenicity against Streptococcus pneumoniae polysaccharides in HIV-infected patients. DESIGN: Randomized controlled phase II trial. METHODS: Two-hundred and twelve patients with CD4 cell counts of 200-500 cells/μl and HIV RNA< 4 log10 copies/ml, regardless of antiretroviral treatment, were randomized to receive either PCV at week 0 and PPV at week 4 (n = 106) or PPV alone at week 4 (n = 106). The proportion of responders to 0, 1-2, 3-4, 5-7 serotypes shared by the two vaccines was evaluated at week 8 and compared using a proportional odds model allowing for adjustment for CD4 cell count, HIV RNA and antiretroviral treatment. RESULTS: At week 8, the profile of response was better in the prime-boost group compared to the PPV group, as determined by the frequency of patients who reached both a twofold increase of serotype-specific IgG levels and IgG level ≥ 1 μg/ml [proportional odds ratio (OR), 2.09; 95% confidence interval (CI), 1.25-3.51; P = 0.005]. No differences in responders were found 4 weeks after PCV or PPV alone, suggesting that PCV primed for response to PPV. Early differences between groups remained significant at week 24 (proportional OR, 2.14; 95% CI, 1.30-3.54; P = 0.003). CONCLUSIONS: In a setting of practical care, a PCV prime-PPV boost strategy enhances the frequency, breadth and magnitude of antibody responses against SPP in HIV-infected adults.",

keywords = "Conjugate vaccine, HIV, Immunogenicity, Pneumococcal vaccine, Priming",

author = "Philippe Lesprit and Ga{\"e}lle P{\'e}drono and Molina, {Jean Michel} and C{\'e}cile Goujard and Girard, {Pierre Marie} and Nathalie Sarrazin and Christine Katlama and Patrick Y{\'e}ni and Pascale Morineau and Delfraissy, {Jean Fran{\c c}ois} and Genevi{\`e}ve Ch{\^e}ne and Yves L{\'e}vy and P. Lesprit and Y. Levy and N. Sarrazin and G. Pedrono and C. Rabian and P. Bursachi and Commoy, {M. J.} and Delfraissy, {J. F.} and F. Denis and B. Fritzell and C. Goujard and R. Salamon and R. Tubiana and Viard, {J. P.} and A. Krivitzky and M. Bentata and S. Makki and R. Mansouri and L. Guillevin and B. Jarousse and Klutse, {A. K.} and G. Obenga and P. Honor{\'e}-Berlureau and Y. Baazia and S. Soreda and Clauvel, {J. P.} and E. Oksenhendler and L. Gerard and J. Delgado and Molina, {J. M.} and {Colin De Verdi{\`e}re}, N. and P. Palmer and I. Madelaine and M. Dupon and Ragnaud, {J. M.} and D. Neau and I. Raymond and I. Garrigue and Dupin, {J. P.} and Ch Boitard and Viard, {J. P.} and {El Marsafy}, S. and R. Lahoulou and A. Mogenet and C. Broissand and Delfraissy, {J. F.} and C. Goujard and D. Pereti and Y. Quertainmont and P. Robquin and O. Segeral and S. Poirier and Rannou, {M. T.} and N. Idri and {Le Tiec}, C. and D. Sicard and D. Salmon and O. Launay and B. Silbermann and C. Desaint and A. Krivine and C. Gu{\'e}rin and A. Sobel and Y. L{\'e}vy and P. Lesprit and Lascaux, {A. S.} and Ch Chesnel and C. Jung and A. Miladi and C. Antoine and F. Bricaire and I. Boubezari and S. Pierre-Fran{\c c}ois and L. Schneider and C. Seuli{\'e} and Fievet, {M. H.} and Girard, {P. M.} and B{\'e}gl{\'e}, {A. M.} and F. Besse and R. Mouchotte and A. Charrois and A. Duaguenel-Nguyen and P. Yeni and I. Fournier and S. Lariven and B. Phung and P. Rala{\"i}mazava and Ch Gaudebout and J. Gerbe and D. Descamps and S. LePoole and J. Reynes and P. Andr{\'e} and V. Baillat and {Le Moing}, V. and C. Merle and M. Vidal and Fond{\`e}re, {J. M.} and I. Roch-Torreilles and F. Raffi and P. Morineau and C. Allavena and B. Bonnet and H. Hue and E. Guarnier and A. Lepelletier and P. Perr{\'e} and O. Aubry and S. Leautez and C. Leroy and I. Suaud and Poirier, {A. S.} and A. Lepelletier and P. Dellamonica and V. Rahelinirina and Sereni, {M. A.} and S. Benhamou and Rigault, {M. Ch} and P. Massip and B. Marchou and M. Alvarez and E. Bonnet and L. Cuzin and M. Obadia and F. Balsarin and M. Barone and M. Heraud and I. Peyranne and F. Mentr{\'e} and P. Morlat and N. Sarrazin and G. Pedrono and I. Tsch{\"o}pe and G. Palmer",

year = "2007",

month = dec,

doi = "10.1097/QAD.0b013e3282887e91",

language = "אנגלית",

volume = "21",

pages = "2425--2434",

journal = "AIDS",

issn = "0269-9370",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "18",

}

Lesprit, P, Pédrono, G, Molina, JM, Goujard, C, Girard, PM, Sarrazin, N, Katlama, C, Yéni, P, Morineau, P, Delfraissy, JF, Chêne, G, Lévy, Y, Lesprit, P, Levy, Y, Sarrazin, N, Pedrono, G, Rabian, C, Bursachi, P, Commoy, MJ, Delfraissy, JF, Denis, F, Fritzell, B, Goujard, C, Salamon, R, Tubiana, R, Viard, JP, Krivitzky, A, Bentata, M, Makki, S, Mansouri, R, Guillevin, L, Jarousse, B, Klutse, AK, Obenga, G, Honoré-Berlureau, P, Baazia, Y, Soreda, S, Clauvel, JP, Oksenhendler, E, Gerard, L, Delgado, J, Molina, JM, Colin De Verdière, N, Palmer, P, Madelaine, I, Dupon, M, Ragnaud, JM, Neau, D, Raymond, I, Garrigue, I, Dupin, JP, Boitard, C, Viard, JP, El Marsafy, S, Lahoulou, R, Mogenet, A, Broissand, C, Delfraissy, JF, Goujard, C, Pereti, D, Quertainmont, Y, Robquin, P, Segeral, O, Poirier, S, Rannou, MT, Idri, N, Le Tiec, C, Sicard, D, Salmon, D, Launay, O, Silbermann, B, Desaint, C, Krivine, A, Guérin, C, Sobel, A, Lévy, Y, Lesprit, P, Lascaux, AS, Chesnel, C, Jung, C, Miladi, A, Antoine, C, Bricaire, F, Boubezari, I, Pierre-François, S, Schneider, L, Seulié, C, Fievet, MH, Girard, PM, Béglé, AM, Besse, F, Mouchotte, R, Charrois, A, Duaguenel-Nguyen, A, Yeni, P, Fournier, I, Lariven, S, Phung, B, Ralaïmazava, P, Gaudebout, C, Gerbe, J, Descamps, D, LePoole, S, Reynes, J, André, P, Baillat, V, Le Moing, V, Merle, C, Vidal, M, Fondère, JM, Roch-Torreilles, I, Raffi, F, Morineau, P, Allavena, C, Bonnet, B, Hue, H, Guarnier, E, Lepelletier, A, Perré, P, Aubry, O, Leautez, S, Leroy, C, Suaud, I, Poirier, AS, Lepelletier, A, Dellamonica, P, Rahelinirina, V, Sereni, MA, Benhamou, S, Rigault, MC, Massip, P, Marchou, B, Alvarez, M, Bonnet, E, Cuzin, L, Obadia, M, Balsarin, F, Barone, M, Heraud, M, Peyranne, I, Mentré, F, Morlat, P, Sarrazin, N, Pedrono, G, Tschöpe, I & Palmer, G 2007, 'Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults', AIDS, vol. 21, no. 18, pp. 2425-2434. https://doi.org/10.1097/QAD.0b013e3282887e91

TY - JOUR

T1 - Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults

AU - Lesprit, Philippe

AU - Pédrono, Gaëlle

AU - Molina, Jean Michel

AU - Goujard, Cécile

AU - Girard, Pierre Marie

AU - Sarrazin, Nathalie

AU - Katlama, Christine

AU - Yéni, Patrick

AU - Morineau, Pascale

AU - Delfraissy, Jean François

AU - Chêne, Geneviève

AU - Lévy, Yves

AU - Lesprit, P.

AU - Levy, Y.

AU - Sarrazin, N.

AU - Pedrono, G.

AU - Rabian, C.

AU - Bursachi, P.

AU - Commoy, M. J.

AU - Delfraissy, J. F.

AU - Denis, F.

AU - Fritzell, B.

AU - Goujard, C.

AU - Salamon, R.

AU - Tubiana, R.

AU - Viard, J. P.

AU - Krivitzky, A.

AU - Bentata, M.

AU - Makki, S.

AU - Mansouri, R.

AU - Guillevin, L.

AU - Jarousse, B.

AU - Klutse, A. K.

AU - Obenga, G.

AU - Honoré-Berlureau, P.

AU - Baazia, Y.

AU - Soreda, S.

AU - Clauvel, J. P.

AU - Oksenhendler, E.

AU - Gerard, L.

AU - Delgado, J.

AU - Molina, J. M.

AU - Colin De Verdière, N.

AU - Palmer, P.

AU - Madelaine, I.

AU - Dupon, M.

AU - Ragnaud, J. M.

AU - Neau, D.

AU - Raymond, I.

AU - Garrigue, I.

AU - Dupin, J. P.

AU - Boitard, Ch

AU - Viard, J. P.

AU - El Marsafy, S.

AU - Lahoulou, R.

AU - Mogenet, A.

AU - Broissand, C.

AU - Delfraissy, J. F.

AU - Goujard, C.

AU - Pereti, D.

AU - Quertainmont, Y.

AU - Robquin, P.

AU - Segeral, O.

AU - Poirier, S.

AU - Rannou, M. T.

AU - Idri, N.

AU - Le Tiec, C.

AU - Sicard, D.

AU - Salmon, D.

AU - Launay, O.

AU - Silbermann, B.

AU - Desaint, C.

AU - Krivine, A.

AU - Guérin, C.

AU - Sobel, A.

AU - Lévy, Y.

AU - Lesprit, P.

AU - Lascaux, A. S.

AU - Chesnel, Ch

AU - Jung, C.

AU - Miladi, A.

AU - Antoine, C.

AU - Bricaire, F.

AU - Boubezari, I.

AU - Pierre-François, S.

AU - Schneider, L.

AU - Seulié, C.

AU - Fievet, M. H.

AU - Girard, P. M.

AU - Béglé, A. M.

AU - Besse, F.

AU - Mouchotte, R.

AU - Charrois, A.

AU - Duaguenel-Nguyen, A.

AU - Yeni, P.

AU - Fournier, I.

AU - Lariven, S.

AU - Phung, B.

AU - Ralaïmazava, P.

AU - Gaudebout, Ch

AU - Gerbe, J.

AU - Descamps, D.

AU - LePoole, S.

AU - Reynes, J.

AU - André, P.

AU - Baillat, V.

AU - Le Moing, V.

AU - Merle, C.

AU - Vidal, M.

AU - Fondère, J. M.

AU - Roch-Torreilles, I.

AU - Raffi, F.

AU - Morineau, P.

AU - Allavena, C.

AU - Bonnet, B.

AU - Hue, H.

AU - Guarnier, E.

AU - Lepelletier, A.

AU - Perré, P.

AU - Aubry, O.

AU - Leautez, S.

AU - Leroy, C.

AU - Suaud, I.

AU - Poirier, A. S.

AU - Lepelletier, A.

AU - Dellamonica, P.

AU - Rahelinirina, V.

AU - Sereni, M. A.

AU - Benhamou, S.

AU - Rigault, M. Ch

AU - Massip, P.

AU - Marchou, B.

AU - Alvarez, M.

AU - Bonnet, E.

AU - Cuzin, L.

AU - Obadia, M.

AU - Balsarin, F.

AU - Barone, M.

AU - Heraud, M.

AU - Peyranne, I.

AU - Mentré, F.

AU - Morlat, P.

AU - Sarrazin, N.

AU - Pedrono, G.

AU - Tschöpe, I.

AU - Palmer, G.

PY - 2007/12

Y1 - 2007/12

N2 - OBJECTIVE: To evaluate whether a strategy combining a prime with a 7-valent conjugate pneumococcal vaccine (PCV) followed by a boost with the 23-valent polysaccharide vaccine (PPV) would improve immunogenicity against Streptococcus pneumoniae polysaccharides in HIV-infected patients. DESIGN: Randomized controlled phase II trial. METHODS: Two-hundred and twelve patients with CD4 cell counts of 200-500 cells/μl and HIV RNA< 4 log10 copies/ml, regardless of antiretroviral treatment, were randomized to receive either PCV at week 0 and PPV at week 4 (n = 106) or PPV alone at week 4 (n = 106). The proportion of responders to 0, 1-2, 3-4, 5-7 serotypes shared by the two vaccines was evaluated at week 8 and compared using a proportional odds model allowing for adjustment for CD4 cell count, HIV RNA and antiretroviral treatment. RESULTS: At week 8, the profile of response was better in the prime-boost group compared to the PPV group, as determined by the frequency of patients who reached both a twofold increase of serotype-specific IgG levels and IgG level ≥ 1 μg/ml [proportional odds ratio (OR), 2.09; 95% confidence interval (CI), 1.25-3.51; P = 0.005]. No differences in responders were found 4 weeks after PCV or PPV alone, suggesting that PCV primed for response to PPV. Early differences between groups remained significant at week 24 (proportional OR, 2.14; 95% CI, 1.30-3.54; P = 0.003). CONCLUSIONS: In a setting of practical care, a PCV prime-PPV boost strategy enhances the frequency, breadth and magnitude of antibody responses against SPP in HIV-infected adults.

AB - OBJECTIVE: To evaluate whether a strategy combining a prime with a 7-valent conjugate pneumococcal vaccine (PCV) followed by a boost with the 23-valent polysaccharide vaccine (PPV) would improve immunogenicity against Streptococcus pneumoniae polysaccharides in HIV-infected patients. DESIGN: Randomized controlled phase II trial. METHODS: Two-hundred and twelve patients with CD4 cell counts of 200-500 cells/μl and HIV RNA< 4 log10 copies/ml, regardless of antiretroviral treatment, were randomized to receive either PCV at week 0 and PPV at week 4 (n = 106) or PPV alone at week 4 (n = 106). The proportion of responders to 0, 1-2, 3-4, 5-7 serotypes shared by the two vaccines was evaluated at week 8 and compared using a proportional odds model allowing for adjustment for CD4 cell count, HIV RNA and antiretroviral treatment. RESULTS: At week 8, the profile of response was better in the prime-boost group compared to the PPV group, as determined by the frequency of patients who reached both a twofold increase of serotype-specific IgG levels and IgG level ≥ 1 μg/ml [proportional odds ratio (OR), 2.09; 95% confidence interval (CI), 1.25-3.51; P = 0.005]. No differences in responders were found 4 weeks after PCV or PPV alone, suggesting that PCV primed for response to PPV. Early differences between groups remained significant at week 24 (proportional OR, 2.14; 95% CI, 1.30-3.54; P = 0.003). CONCLUSIONS: In a setting of practical care, a PCV prime-PPV boost strategy enhances the frequency, breadth and magnitude of antibody responses against SPP in HIV-infected adults.

KW - Conjugate vaccine

KW - HIV

KW - Immunogenicity

KW - Pneumococcal vaccine

KW - Priming

UR - http://www.scopus.com/inward/record.url?scp=36348990172&partnerID=8YFLogxK

U2 - 10.1097/QAD.0b013e3282887e91

DO - 10.1097/QAD.0b013e3282887e91

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 18025879

AN - SCOPUS:36348990172

SN - 0269-9370

VL - 21

SP - 2425

EP - 2434

JO - AIDS

JF - AIDS

IS - 18

ER -

Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this